Hybrid Continuous-Flow Total Artificial Heart
Autor: | Carson S. Fox, Steven G. Chopski, Paul E. Allaire, Robert M. Mentzer, Joseph W. Rossano, Nohra M. Murad, Francisco A. Arabia, Amy L. Throckmorton |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Biomedical Engineering Medicine (miscellaneous) Bioengineering 030204 cardiovascular system & hematology Extracorporeal law.invention Biomaterials 03 medical and health sciences Impeller 0302 clinical medicine law Internal medicine Artificial heart medicine Continuous flow business.industry General Medicine Blood flow medicine.disease Blood pump 030228 respiratory system Ventricular assist device Heart failure Cardiology business |
Zdroj: | Artificial Organs. 42:500-509 |
ISSN: | 0160-564X |
Popis: | Clinical studies using total artificial hearts (TAHs) have demonstrated that pediatric and adult patients derive quality-of-life benefits from this form of therapy. Two clinically-approved TAHs and other pumps under development, however, have design challenges and limitations, including thromboembolic events, neurologic impairment, infection risk due to large size and percutaneous drivelines, and lack of ambulation, to name a few. To address these limitations, we are developing a hybrid-design, continuous-flow, implantable or extracorporeal, magnetically-levitated TAH for pediatric and adult patients with heart failure. This TAH has only two moving parts: an axial impeller for the pulmonary circulation and a centrifugal impeller for the systemic circulation. This device will utilize the latest generation of magnetic bearing technology. Initial geometries were established using pump design equations, and computational modeling provided insight into pump performance. The designs were the basis for prototype manufacturing and hydraulic testing. The study results demonstrate that the TAH is capable of delivering target blood flow rates of 1-6.5 L/min with pressure rises of 1-92 mm Hg for the pulmonary circulation and 24-150 mm Hg for the systemic circulation at 1500-10 000 rpm. This initial design of the TAH was successful and serves as the foundation to continue its development as a novel, more compact, nonthrombogenic, and effective therapeutic alternative for infants, children, adolescents, and adults with heart failure. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |